Quality Grade Downgrade and Its Implications
The downgrade to a below average quality grade from an earlier average rating signals a weakening in the company’s financial health and operational efficiency. SMS Pharmaceuticals’ Mojo Score currently stands at 43.0, which is firmly in the Sell territory, indicating that the company’s fundamentals no longer support a positive outlook. This contrasts with many of its peers in the Pharmaceuticals & Biotechnology sector, such as Ajanta Pharma, Gland Pharma, and Astrazeneca Pharma, which maintain good quality grades.
Return Ratios Show Signs of Strain
Return on Capital Employed (ROCE) and Return on Equity (ROE) are critical indicators of a company’s profitability and capital efficiency. SMS Pharmaceuticals’ average ROCE is 10.39%, while its average ROE is 9.24%. Both metrics are modest and have contributed to the downgrade, especially when compared to sector peers who typically exhibit stronger returns. For instance, companies like Ajanta Pharma and Gland Pharma consistently deliver higher returns, reflecting better capital utilisation and shareholder value creation.
While these returns are positive, they are not sufficiently robust to inspire confidence in sustained growth or superior profitability. The relatively low ROE suggests that the company is generating limited profit from shareholders’ equity, which may be a concern for investors seeking higher returns in the pharmaceutical space.
Growth Trends and Consistency
Over the past five years, SMS Pharmaceuticals has recorded a sales growth rate of 9.51% and an EBIT growth rate of 5.95%. These figures indicate moderate expansion but fall short of the more aggressive growth rates seen in some competitors. The company’s sales to capital employed ratio averages 0.79, which points to suboptimal utilisation of capital in generating revenue. This inefficiency may be a factor in the company’s below average quality rating.
Moreover, the company’s dividend payout ratio is a mere 4.08%, signalling a conservative approach to returning cash to shareholders. While this could imply reinvestment into the business, the lack of strong growth and returns raises questions about the effectiveness of such reinvestment strategies.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Debt Levels and Financial Leverage
SMS Pharmaceuticals’ debt metrics reveal a moderate leverage position but with some cautionary signals. The average Debt to EBITDA ratio stands at 2.95, which is on the higher side for a pharmaceutical company, indicating that earnings before interest, tax, depreciation, and amortisation are only just sufficient to cover debt obligations. The average Net Debt to Equity ratio is 0.46, reflecting a moderate reliance on debt financing relative to equity.
Importantly, the EBIT to Interest coverage ratio averages 4.06, suggesting that the company earns just over four times its interest expense, which is adequate but not comfortably high. This level of coverage leaves limited room for earnings volatility or increased interest costs, potentially increasing financial risk.
Another point of concern is the relatively high pledged shares percentage at 17.99%, which may indicate promoter reliance on pledged stock for financing. Institutional holding is low at 3.33%, signalling limited confidence from large investors or funds, which could impact liquidity and valuation.
Stock Performance Versus Market Benchmarks
Despite the fundamental concerns, SMS Pharmaceuticals has delivered impressive stock returns over longer periods. The stock has gained 41.45% over the past year and an extraordinary 335.13% over three years, significantly outperforming the Sensex, which returned -6.40% and 23.62% respectively over the same periods. Even over five and ten years, SMS Pharma’s returns of 115.01% and 315.78% dwarf the Sensex’s 51.05% and 195.54% gains.
However, recent short-term performance has been weaker, with the stock declining 6.89% in the past week and 6.63% over the last month, while the Sensex showed modest positive or flat returns. This recent weakness may reflect market concerns about the company’s deteriorating quality metrics and the downgrade to Sell.
Holding SMS Pharmaceuticals Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Comparative Industry Positioning
Within the Pharmaceuticals & Biotechnology sector, SMS Pharmaceuticals’ below average quality rating places it behind many of its peers who maintain good or average grades. Companies such as Ajanta Pharma, Gland Pharma, and Emcure Pharma continue to demonstrate stronger growth, higher returns, and better capital efficiency. This relative underperformance may limit SMS Pharma’s ability to attract institutional investors and capital inflows, which are crucial for scaling operations and innovation in this competitive industry.
Outlook and Investor Considerations
The downgrade to Sell and the below average quality grade reflect a cautious outlook on SMS Pharmaceuticals’ fundamentals. While the company has delivered strong long-term stock returns, the recent deterioration in return ratios, moderate growth rates, and elevated leverage raise concerns about sustainability. Investors should weigh these factors carefully against the company’s valuation and sector dynamics.
For those holding SMS Pharmaceuticals, it may be prudent to monitor upcoming quarterly results closely for signs of improvement in profitability and capital management. Additionally, comparing SMS Pharma with higher-quality peers could reveal better risk-adjusted opportunities within the sector.
Summary of Key Financial Metrics
To recap, SMS Pharmaceuticals’ key averages over recent years are:
- Sales Growth (5 years): 9.51%
- EBIT Growth (5 years): 5.95%
- EBIT to Interest Coverage: 4.06 times
- Debt to EBITDA: 2.95 times
- Net Debt to Equity: 0.46
- Sales to Capital Employed: 0.79
- Tax Ratio: 24.55%
- Dividend Payout Ratio: 4.08%
- Pledged Shares: 17.99%
- Institutional Holding: 3.33%
- ROCE: 10.39%
- ROE: 9.24%
These figures collectively underpin the company’s below average quality grade and the recent downgrade in rating.
Conclusion
SMS Pharmaceuticals Ltd’s recent downgrade to Sell by MarketsMOJO highlights the challenges the company faces in maintaining strong business fundamentals. While the stock has rewarded investors handsomely over the long term, the current quality metrics suggest caution. Investors should consider the company’s moderate returns, elevated debt levels, and below average growth consistency when making portfolio decisions. Comparing SMS Pharmaceuticals with higher-quality peers in the Pharmaceuticals & Biotechnology sector may offer more attractive risk-reward profiles going forward.
53% Discount is LIVE - Get MojoOne + Stock of the Week for 3 Years Start Today
